Table 3.
Comparison of curative effects, metastasis and recurrence
| Factors | THP group | DOX group | P value |
|---|---|---|---|
|
| |||
| (n=47) | (n=49) | ||
| Follow-up (months) | 63.7 ± 16.9 | 55.1 ± 19.5 | 0.342 |
| Histotype response | |||
| Good | 29 (61.7%) | 29 (59.2%) | 0.482 |
| Poor | 18 (38.3%) | 20 (40.8%) | |
| Surgery | |||
| Limb salvage | 35 (74.4%) | 33 (67.3%) | 0.294 |
| Amputation | 12 (25.6%) | 16 (32.7%) | |
| Surgical margins | |||
| Adequate | 44 (93.6%) | 44 (89.8%) | 0.381 |
| Inadequate | 3 (6.4%) | 5 (10.2%) | |
| 5-year DFS | 33 (70.2%) | 26 (53.1%) | 0.064 |
| 5-year OS | 37 (78.7%) | 30 (61.2%) | 0.049 |
| Time to relapse (months) | 26.9 ± 15.1 | 23.0 ± 15.4 | 0.453 |
| Number of relapses | 14 (29.8%) | 23 (46.9%) | 0.064 |
| All lung metastases | 11 (23.4%) | 20 (40.8%) | 0.053 |
| (lung, lung + bone or lung + local) | |||
| Isolated lung metastases | 9 (19.1%) | 18 (36.7%) | 0.045 |
| All bone metastases | 2 (4.3%) | 3 (6.1%) | 0.520 |
| (bone, bone + lung, bone + local) | |||
| Isolated bone metastases | 1 (2.1%) | 1 (2.0%) | 0.742 |
| All local recurrence | 2 (4.3%) | 3 (6.1%) | 0.520 |
| (local, local + bone, local + lung) | |||
| Isolated local recurrence | 1 (2.1%) | 1 (2.0%) | 0.742 |
| Isolated other site | 1 (2.1%) | 0 (0%) | 0.490 |
| Post-relapse outcome | |||
| DFS after relapse | 1 (7.1%) | 2 (8.7%) | 0.683 |
| Alive with disease | 3 (21.4%) | 2 (8.7%) | 0.269 |
| Death | 11 (78.6%) | 20 (87.0%) | 0.407 |
| Time to death (months) | 16.0 ± 4.0 | 17.0 ± 5.0 | 0.850 |
Continuous variables are presented as means ± standard deviations (SD), and categorical data are presented as numbers (percentages). Differences between the two groups were analyzed by Fisher’s exact test, χ2 test or independent-samples t-test according to the data distribution. DFS, disease-free survival; OS, overall survival.